论文部分内容阅读
目的探讨头孢哌酮/舒巴坦联合胸腺肽治疗耐药肺炎克雷伯菌肺炎的临床治疗效果及应用价值,重点观察临床治疗效果及对血C-反应蛋白和降钙素原的影响。方法选择2010年1月-2013年1月医院治疗的耐药肺炎克雷伯菌肺炎患者86例,将其随机分为观察组和对照组,每组各43例,对照组患者给予头孢哌酮/舒巴坦治疗,观察组患者给予头孢哌酮/舒巴坦联合胸腺肽治疗,观察两组治疗效果;采用SPSS l5.0软件进行统计分析。结果治疗总有效率观察组为88.37%、对照组为60.47%,经统计分析,差异有统计学意义(P<0.05);观察组患者治疗后C-反应蛋白(14.57±3.28)mg/L、降钙素原(0.24±0.01)ng/ml;对照组患者治疗后C-反应蛋白为(22.62±5.06)mg/L、降钙素原为(0.29±0.02)ng/ml,观察组降低程度优于对照组,经统计分析比较,差异有统计学意义(P<0.05)。结论头孢哌酮/舒巴坦联合胸腺肽治疗耐药肺炎克雷伯菌肺炎疗效可靠,能够纠正患者细胞炎症因子的平衡,值得在临床推广使用。
Objective To investigate the clinical effect and clinical value of cefoperazone / sulbactam combined with thymosin in the treatment of drug-resistant Klebsiella pneumoniae, and to observe the effect of clinical treatment and the effect of C-reactive protein and procalcitonin. Methods 86 patients with drug resistant Klebsiella pneumoniae pneumonia were selected from January 2010 to January 2013 in our hospital. They were randomly divided into observation group and control group, with 43 cases in each group. Patients in the control group were treated with cefoperazone / Sulbactam treatment, patients in observation group were given cefoperazone / sulbactam combined with thymosin, and the therapeutic effect was observed. The data were analyzed by SPSS 15.0 software. Results The total effective rate of observation group was 88.37% in the observation group and 60.47% in the control group, and the difference was statistically significant (P <0.05). The C-reactive protein (14.57 ± 3.28) mg / L, (0.24 ± 0.01) ng / ml, procalcitonin (0.24 ± 0.01) ng / ml and control group were (22.62 ± 5.06) mg / L and Compared with the control group, the difference was statistically significant (P <0.05). Conclusion Cefoperazone / sulbactam combined with thymosin is effective in treating Klebsiella pneumoniae resistant to pneumonia, which can correct the balance of inflammatory cytokines in patients and is worthy of clinical application.